New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
08:58 EDTPPHM, PNT, SNTAThree pharma companies have good partnering prospects, says Roth Capital
Roth Capital believes that Peregrine (PPHM), Palatin (PTN), and Synta (SNTA) have good odds of signing partnership deals in the "relative near term." The firm keeps Buy ratings on all three stocks.
News For PPHM;PNT;SNTA From The Last 14 Days
Check below for free stories on PPHM;PNT;SNTA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2014
08:02 EDTSNTASynta sells $5M in common stock directly to affiliate of board member
Subscribe for More Information
April 8, 2014
07:22 EDTPPHMBiotech Industry Organization to hold a conference
Subscribe for More Information
April 7, 2014
08:29 EDTPPHMPeregrine reports supporting data for combining bavituximab with irradiation
Peregrine Pharmaceuticals announced data from studies demonstrating that an equivalent antibody to Peregrine's lead immunotherapeutic antibody candidate bavituximab administered with stereotactic body radiation therapy, or SBRT, showed a 100% improvement in survival and favorable tumor eradication in a model of non-small cell lung cancer, or NSCLC, compared to irradiation alone. These data were presented yesterday at the 105th Annual Meeting of the American Association for Cancer Research, or AACR, being held in San Diego, California from April 5-9, 2014. Bavituximab is an investigational immunotherapy currently being evaluated in NSCLC as part of the SUNRISE pivotal Phase III clinical trial.
07:27 EDTPPHMAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use